作者: Bradford Hirsch , Amy Abernethy
DOI: 10.3390/JPM3010001
关键词:
摘要: Cancer care is often inconsistently delivered with inadequate incorporation of patient values and objective evidence into decision-making. Utilization time limited trials predefined decision points that are based on iteratively updated best evidence, tools inform providers about a patient’s experience values, known information disease will allow superior matched to be delivered. Personalized medicine does not merely refer the genetic clinical care, it involves utilization wide array data relevant many which readily available at bedside today. By pushing uptake personalized matching today, clinicians can better address triple aim improved health, lowers costs, enhanced experience, we prepare health landscape for iterative inclusion progressively more sophisticated as newer tests become support paradigm.